<DOC>
	<DOCNO>NCT02526953</DOCNO>
	<brief_summary>The purpose study determine whether combination paclitaxel , capecitabine , mitomycin intensity-modulated radiotherapy effective standard combination capecitabine , mitomycin intensity-modulated radiotherapy ( IMRT ) patient squamous-cell anal cancer .</brief_summary>
	<brief_title>Efficacy Study Chemoradiotherapy With Without Paclitaxel Squamous-cell Anal Carcinoma Patients</brief_title>
	<detailed_description>This trial aim investigate efficacy chemoradiotherapy without paclitaxel squamous-cell anal cancer . This prospective multicenter open-label randomized phase III clinical trial . Patients randomize use online randomization system receive either standard IMRT capecitabine mitomycin IMRT capecitabine , mitomycin paclitaxel . A stratification perform base T stage , N stage clinical center . Doses capecitabine mitomycin experimental group reduce well treatment tolerance . The target accrual 157 patient treatment arm ( include 10 % potential data loss ) base potential benefit 15 % 3-yr disease-free survival ( 70 % vs 85 % ) , α=0,05 , power 80 % experimental arm . An interim analysis plan 50 % patient reach 3-year followup . Pelvic Magnetic Resonance Imaging ( MRI ) perform patient stag followup . Pelvic MRI histological diagnosis subject central review . Conduction study data collection control local institutional board .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Anus Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Informed consent Histologically verify squamouscell anal cancer Stage IIIIB ( Union International Cancer Control ( UICC ) TNM classification v7 ) Eastern Cooperative Oncology Group ( ECOG ) status 02 HIV ( Human Immunodeficiency Virus ) negative Haemoglobin ( HGB ) &gt; 90 g/L Platelet Count ( PLT ) &gt; 120x10*9/L Serum creatinine &lt; 150 µmol/L Total bilirubin &lt; 25 µmol/L inability obtain informed consent distant metastases synchronous metachronous tumor previous chemotherapy radiotherapy clinically significant cardiovascular disorder ( myocardial infarction &lt; 6 month visit , stroke &lt; &lt; 6 month visit , instable angina &lt; 3 month visit , arrhythmia , uncontrolled hypertension &gt; 160/100 mm hg clinically significant neurological disorder previous neuropathy 2 high current infection heavy systemic disease pregnancy , breastfeed ulcerative colitis individual intolerance treatment component proven dihydropyrimidine dehydrogenase ( DPD ) deficiency participation clinical trial psychiatric disorder , render patient unable follow instruction understand his/her condition technical inability perform pelvic MRI inability longterm followup patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>anal cancer</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>intensity-modulated radiotherapy</keyword>
	<keyword>paclitaxel</keyword>
</DOC>